Antibody cocktail to treat Covid-19 now in India. What is it? Who should take the therapy?
Antibody cocktail is said to reduce the chance of hospitalisation by 70 per cent in patients with mild to moderate Covid-19 symptoms. Here is all you need to know about the therapy
Indiatoday.in
India Today Web Desk
New Delhi
May 27, 2021UPDATED: May 27, 2021 13:44 IST
Regeneron and Roche's antibody cocktail received emergency-use authorisation in India on May 5 (File)
An 84-year-old man from Haryana, who was the first Covid-19 patient in India to receive an antibody drug cocktail authorised by the Centre earlier this month, has been discharged from hospital. Mohabbat Singh was administered a cocktail of Casirivimab and Imdevimab, developed by Regeneron and Roche.
The antibody cocktail shot into the limelight after it was used to treat former United States President Donald Trump last year. The therapy is said to reduce the chance of hospitalisation by 70 per cent in patients with mild to moderate Covid-19 symptoms.
What is an antibody cocktail?
The therapy is literally a cocktail of two monoclonal antibodies. Antibodies are proteins that the body generates to defend itself against any disease. Monoclonal antibodies are artificially created in a laboratory and tailor-made to fight a particular disease.
RECOMMENDED
Casirivimab and imdevimab, which are part of the antibody cocktail produced by Switzerland-based Roche, are specifically directed against the spike protein of SARS-CoV-2. They block the virus's attachment and subsequent entry into human cells. Using two antibodies protects against the body's resistance to them.
Who should take antibody cocktail?
The antibody cocktail is to be administered for treatment of patients with mild to moderate symptoms in adults and who are at high risk of developing severe Covid-19 disease.
84-year-old Haryana man, first in India to get antibody cocktail against Covid-19
Visuals from Medanta Hospital (ANI)
Visuals from Medanta Hospital (ANI)
2 min read . Updated: 26 May 2021, 04:37 PM IST
Shalini Bhardwaj, ANI
The cocktail of two fast acting antibodies-Casirivimab and Imdevimab is seen as a cutting-edge treatment that will provide protection to Covid-19 patients with mild and moderate symptoms
GURUGRAM : An 84-year-old man from Haryana has become the first person in India to be administered the Covid drug cocktail, which came into limelight after it was administered to former US President Donald Trump when he tested positive for the virus last year.
Mohabbat Singh, who was under treatment for the last five days at Gurugram's Medanta Hospital was on Tuesday given the drug over a 30 minute intravenous supply.
MORE FROM THIS SECTIONSee All
Uttarakhand Chief Minister Tirath Singh Rawat
Uttarakhand rolls out heavy fines for noise pollution
Three out of the bottom five ESG scorers are for metals & mining companies (Vedanta, NMDC and Coal India). ONGC, UPL and DLF also lied within the bottom 10, according to Edelweiss' ESG Scorecard & Ratings for India’s top 100 companies.
Indian IT, BFSI sectors lead on ESG parameters; metals, ....
Travelers flock to Las Vegas ahead of Memorial Day weekend at McCarran International Airport in Las Vegas, Nevada, U.S., May 28
US considering vaccine passports for Americans travelin ....
A view of the beds inside a hospital for COVID-19 patients. Representative image
Hyderabad private hospital's covid treatment license re ....
The cocktail of two fast acting antibodies-Casirivimab and Imdevimab is seen as a cutting-edge treatment that will provide protection to Covid-19 patients with mild and moderate symptoms before their condition deteriorates and they require hospitalization.
The first batch of the Roche antibody cocktail drug arrived in the country on Monday, according to an official announcement by Roche India and Cipla Limited.
"If these antibodies are injected into a patient infected with the Covid-19 virus at an early stage when the virus is trying to multiply then it blocks the virus from entering the cells of the patient from where it derives nutrition to multiply. So by blocking the virus they are stopping the multiplication of the virus and finally the virus spikes. It is one of the blocking mechanisms that is working against the Covid-19 virus," Doctor Naresh Trehan, Chairman and MD of Medanta hospital told ANI.
Dr Tehran further said that the antibodies are also effective against the new variant B.1.617.2 and this has been verified in laboratories as well.
The antibody cocktail therapy is not recommended for patients who are hospitalized due to severe Covid-19, or those who require oxygen therapy due to Covid-19 or who require an increase in baseline oxygen flow rate due to Covid-19 and in patients on chronic oxygen therapy due to underlying non-Covid-19 related comorbidity.
"It has been tested and used extensively in the US and Europe and the experience shows that (it works) when given timely, that means the first seven days of viral replication stage or when the virus multiplies. So, by blocking it then you are reducing the severity of the disease in everybody, but also in those who had a severe infection because of comorbidities along with their age and also a high viral load. It has been found effective when given on time, the sooner you give it more effective it is," Dr Trehan said.
TRENDING STORIESSee All
According to the Ministry, waiting time at toll plazas has reduced drastically after the implementation of the FASTag.
New toll plaza rules: No toll tax to be paid if wait ti ....
The headquarters of India's HDFC bank is pictured in Mumbai.
RBI imposes ₹10 crore penalty on HDFC Bank
Petrol, diesel prices
Petrol price crosses ₹100 mark in Mumbai as fuel price ....
The feature will also be extended to other products of the company (Image for representation).
Zydus Cadila's secret scratch code in critical drug pac ....
This FDA-approved therapy demonstrated good efficacy in Phase 1/2 and Phase 3 studies by reducing Covid-19 related hospitalization and death by 70 per cent. Approved by the Drugs Controller General of India (DCGI), this single dose infusion-based treatment can be provided on an outpatient or daycare basis and marks a dramatic shift in Covid-19 care in India.
"We are glad to now have access to Monoclonal Antibody Therapy in India. This fast and effective treatment for COVID -19 will save patients at the highest risk from falling critically ill, getting hospitalized or possibly dying of complications from Covid-19. We look forward to serving our patients with this therapy and saving more lives," said Dr Naresh Trehan.
The doctor, however, said that patients are advised to check with their doctor if monoclonal antibody therapy may be beneficial to them in the treatment of their Covid-19 infection. (ANI)
Antibody cocktail can help recover Covid-19 patients within one week: Dr Nageshwar Reddy
Dr Reddy said use of antibody cocktail treatment for Covid-19 patients can help them recover from the disease within one week. However, the treatment should be given only in hospital settings.
ADVERTISEMENT
Ashish Pandey
Hyderabad
May 27, 2021UPDATED: May 27, 2021 22:10 IST
Dr D Nageshwar Reddy, chairperson AIG Hospitals, Hyderabad.
Of late, a treatment based on monoclonal antibody cocktail is being seen as an effective way to handle Covid-related complications in patients. The central government has approved its use in India and hospitals have started adopting the treatment.
Speaking about it, Dr D Nageshwar Reddy, chairperson AIG Hospitals Hyderabad, said the cocktail can help Covid-19 patients recover within just one week.
He said the AIG Hospitals has started using this treatment for Covid-19 patients and is conducting a large study to understand its efficacy on mutated variants of the virus causing Covid-19.
ALSO READ | Antibody cocktail to treat Covid-19 now in India. What is it? Who should take the therapy?
PauseUnmute
Fullscreen
VDO.AI
CHECK THESE OUT
MORE
Octogenarian Covid-19 patient, who received monoclonal antibody therapy, back home
Octogenarian Covid-19 patient, who received monoclonal antibody therapy, back home
RECOMMENDED
Antibody cocktail to treat Covid-19 now in India. What is it? Who should take the therapy?
Antibody cocktail to treat Covid-19 now in India. What is it? Who should take the therapy?
RECOMMENDED
"Within one week, this treatment can help patients become RT-PCR negative. At AIG, we are doing a major study where we are looking at the efficacy of this treatment against the double mutant variant of the virus," Dr Reddy said.
The antibody cocktail shot into the limelight after it was used to treat former US President Donald Trump last year. The therapy is said to reduce the chance of hospitalisation by 70 per cent in patients with mild to moderate Covid-19 symptoms.
''The real-world evidence of these monoclonal antibodies is yet to be established, but clinical studies published in peer-reviewed journals, including the New England Journal of Medicine, are encouraging as they have shown to reduce hospitalisation or death by over 70 per cent, including a drastic reduction in viral clearance," Dr Reddy said.
ADVERTISEMENT
What is an antibody cocktail?
The therapy is literally a cocktail of two monoclonal antibodies. Antibodies are proteins that the body generates to defend itself against any disease. Monoclonal antibodies are artificially created in a laboratory and tailor-made to fight a particular disease.
ALSO READ | Covid Antibody Cocktail will reduce hospitalisation, can be given to children: Dr Naresh Trehan
Casirivimab and imdevimab, which are part of the antibody cocktail produced by Switzerland-based Roche, are specifically directed against the spike protein of SARS-CoV-2.
They block the virus's attachment and subsequent entry into human cells. Using two antibodies protects against the body's resistance to them.
Treatment best suited for elderly, diabetic: Dr Reddy
Speaking about the antibody cocktail treatment, Dr Reddy said patients aged more than 65 years, those with obesity, uncontrolled diabetes, cardiovascular issues or those who are under immunosuppressants are the ideal candidates for this treatment.
ALSO READ | Covid: Roche’s antibody cocktail launched in India at Rs 59,750 per patient, Cipla to market it
ADVERTISEMENT
"This can also be given to patients who are aged more than 55 years if they have heart-related issues," he said.
However, Dr Reddy cautioned that pregnant women should not be given this treatment, and patients who recover following this treatment should wait for at least three months to get vaccinated.
He also added that the antibody cocktail should only be given in a hospital setting where there is provision to activate emergency medical system immediately following any infusion-related adverse reaction.
గుడ్న్యూస్ :- ఈ ఇంజక్షన్ వేస్తే కరోనా ఖతం..!
కరోనా రోగులకు ఓ గుడ్ న్యూస్.. ఇప్పుడు కరోనా చికిత్స కోసం ఓ కొత్త ఔషధం వచ్చేసింది. ఇంజక్షన్ రూపంలో ఈ ఔషధం దొరుకుతోంది. ఈ ఇంజక్షన్ ఒక్క డోస్ వేస్తే చాలు.. వారం రోజుల్లో కరోనా నుంచి కోలుకుంటారు.
అవును ఇది నిజమే.. ఈ విషయాన్ని ధ్రువీకరిస్తున్నారు ఆసియన్ ఇన్స్టిట్యూట్ ఆఫ్ గ్యాస్ట్రో ఎంట్రాలజీ వైద్యులు డాక్టర్ నాగేశ్వర్ రెడ్డి. ఇంతకీ ఆ ఇంజక్షన్ ఏంటి.. దాని కథాకమామీషు ఏంటో తెలుసుకుందాం.
ఈ ఇంజక్షన్ పేరు ‘మోనోక్లోనల్ యాంటీబాడీ.. దీన్ని కాక్టెయిల్ యాంటీబాడీ అని కూడా పిలుస్తున్నారు. ఈ ఇంజక్షన్తో మెరుగైన ఫలితాలు లభిస్తున్నాయి. భారత ప్రభుత్వం తాజాగా ఈ చికిత్సకు అనుమతించింది. ఈ ఇంజక్షన్తో కరోనా రోగులు 7-10 రోజుల్లో పూర్తిగా కోలుకుంటున్నారు. రోగుల శరీరం నుంచి వైరస్ మటుమాయమవుతుంది.
ఇప్పుడు ఈ చికిత్స హైదరాబాద్ లోనూ అందుబాటులోకి వచ్చింది. కరోనా తీవ్రత అధికంగా ఉన్నవారికి ఈ ఇంజక్షన్ ఇస్తే.. ఎక్కవ ప్రయోజనం ఉంటుందని ఏషియన్ ఇన్స్టిట్యూట్ ఆఫ్ గ్యాస్ట్రోఎంటరాలజీ ఛైర్మన్ డాక్టర్ డి.నాగేశ్వరరెడ్డి తెలిపారు.
65 ఏళ్లు దాటిన వారికి, స్థూలకాయులకు అంటే ‘బాడీ మాస్ ఇండెక్స్’ 35 కంటే ఎక్కువగా ఉన్నవారికి ఈ ఇంజక్షన్ బాగా ఉపయోగపడుతుంది. దీర్ఘకాలిక మూత్రపిండాల వ్యాధి పీడితులకు, ఎంతోకాలంగా మధుమేహానికి చికిత్స పొందుతున్నవారికి కరోనా వస్తే ఈ ఇంజక్షన్ ప్రాణదాతగా చెప్పుకోవచ్చు.
రోగ నిరోధక శక్తిని తగ్గించే ఔషధాలను వినియోగిస్తున్నవారికి అంటే.. క్యాన్సర్ రోగులు, అవయవ మార్పిడి చేయించుకున్నవారికి కూడా ఈ ఇంజక్షన్ ఇవ్వొచ్చని నాగేశ్వరరెడ్డి తెలిపారు.
55 ఏళ్లు దాటి అధిక రక్తపోటు, గుండెజబ్బు ఉన్న బాధితులకు కూడా ఈ ఇంజక్షన్ ఇవ్వొచ్చు. క్రానిక్ అబ్స్ట్రక్టివ్ పల్మనరీ డిసీజ్, ఆస్తమాతో బాధపడుతున్న వారికి, దీర్ఘకాలిక అనారోగ్య సమస్యలు, ముప్పు తీవ్రత ఉంటే 12 ఏళ్లు దాటిన వారికి, బాలింతలకు కూడా ఈ ఇంజక్షన్ ఇవ్వవచ్చని చెబుతున్నారు.
తాజాగా హరియాణలో ఓ 84 వృద్ధుడు ఈ ఇంజక్షన్ ద్వారా కోలుకున్నారు. దీని విలువ రూ. 60 వేల వరకూ ఉంటుంది.
No comments:
Post a Comment